Mineralys Therapeutics
PublicMineralys Therapeutics is now publicly traded
The data on this page reflects Mineralys Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Feb 9, 2023
Last Round
Follow-on Offering
Sep 4, 2025
Total Funding Raised
$786.3M
Company Overview
Mineralys (NAS: MLYS) is a biopharmaceutical company focused on developing innovative treatments for diseases associated with elevated aldosterone levels, including its lead product candidate, lorundrostat, an oral selective aldosterone synthase inhibitor aimed at managing uncontrolled and resistant hypertension.
Sector
Healthcare
AI Layer
Non-AI
Keywords
Mineralys Therapeutics Comparables
Compare Mineralys Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Retension Pharmaceuticals | 78% | |
| Mandeville Therapeutics | 55% |
Mineralys Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Sep 4, 2025 | ||||
| Private Placement | Feb 8, 2024 | ||||
| IPO | Feb 9, 2023 | ||||
| Series B | Jun 8, 2022 | ||||
| Series A | Apr 6, 2021 |
Mineralys Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Evercore ISI | IPO, Follow-on Offering |
| HealthCor Partners Management | Series B |
| RA Capital Management | IPO, Series B, Private Placement |
| TCG Crossover | Private Placement |
| Guggenheim Securities | IPO |
| Phase4 Partners | Series B |
| Andera Partners | Series B |
Mineralys Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access